Subjects: ANTICOAGULANTES, ESTUDOS PROSPECTIVOS, FIBRILAÇÃO ATRIAL, QUIMIOTERAPIA COMBINADA
ABNT
NICOLAU, José Carlos et al. Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial. Drugs, v. 80, n. 10, p. 995-1005, 2020Tradução . . Disponível em: https://doi.org/10.1007/s40265-020-01323-x. Acesso em: 01 set. 2024.APA
Nicolau, J. C., Bhatt, D. L., Hohnloser, S. H., Kimura, T., Lip, G. Y. H., Miede, C., et al. (2020). Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial. Drugs, 80( 10), 995-1005. doi:10.1007/s40265-020-01323-xNLM
Nicolau JC, Bhatt DL, Hohnloser SH, Kimura T, Lip GYH, Miede C, Nordaby M, Oldgren J, Steg PG, Berg JM ten. Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial [Internet]. Drugs. 2020 ; 80( 10): 995-1005.[citado 2024 set. 01 ] Available from: https://doi.org/10.1007/s40265-020-01323-xVancouver
Nicolau JC, Bhatt DL, Hohnloser SH, Kimura T, Lip GYH, Miede C, Nordaby M, Oldgren J, Steg PG, Berg JM ten. Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial [Internet]. Drugs. 2020 ; 80( 10): 995-1005.[citado 2024 set. 01 ] Available from: https://doi.org/10.1007/s40265-020-01323-x